FDA floats oncology authorization shake-up, pitching 'one-trial' model for accelerated and full approval

The FDA is planning to shake up its approach to the accelerated approval of oncology drugs—and wants to know what you think of its proposals. In draft guidance, the agency outlined plans to move away from single-arm studies and instead favor randomized controlled trials that can potentially serve as the basis for both accelerated and full approval.